The Copenhagen Memory Clinic was established in 1995 and since 2007 a new national center for research and education was established, together forming the Danish Dementia Research Centre (DDRC). Our research and innovation programs have continuously been informed by clinical experience and inspired by the needs of our patients. The link between patient care, research, and education forming together a comprehensive dementia center is therefore of crucial importance. In this review, we present an overview of the clinical program at the Copenhagen Memory Clinic, currently receiving 2.000 new referrals per year. We also present the Copenhagen Memory Clinic Cohort and the associated biobank, as well as clinical, translational and epidemiological research programs performed at DDRC during the past 30 years. Funded in part by the Danish Ministry of Health, our national outreach, professional networks and educational programs are also outlined. From its inception and onwards the primary focus of the DDRC has been with the patients, aiming to continuously improve our clinical service based on research and innovation and to improve the quality of care nationwide. We welcome requests for collaboration on research, innovation and education from international colleagues and research centers.
Alzheimer Europe. Dementia in Europe Yearbook 2019: Estimating the prevalence of dementia in Europe, 2019.
3.
FolsteinMFFolsteinSEMcHughPR. ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198.
4.
PfefferRIKurosakiTTHarrahCH, et al.Measurement of functional activities in older adults in the community. J Gerontol1982; 37: 323–329.
5.
StokholmJVogelAJohannsenP, et al.Validation of the Danish Addenbrooke’s cognitive examination as a screening test in a memory clinic. Dement Geriatr Cogn Disord2009; 27: 361–365.
6.
RingkøbingSPLarsenIUJørgensenK, et al.Cognitive screening tests in Huntington gene mutation carriers: examining the validity of the mini-mental state examination and the Montreal cognitive assessment. J Huntingtons Dis2020; 9: 59–68.
7.
StoreyJERowlandJTJConfortiDA, et al.The Rowland universal dementia assessment scale (RUDAS): a multicultural cognitive assessment scale. Int Psychogeriatr2004; 16: 13–31.
8.
NielsenTRSegersKVanderaspoildenV, et al.Validation of a brief multicultural cognitive examination (MCE) for evaluation of dementia. Int J Geriatr Psychiatry2019; 34: 982–989.
9.
FrederiksenKSNielsenTRWinbladB, et al.European academy of neurology/European Alzheimer’s disease consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment. Eur J Neurol2021; 28: 2147–2155.
10.
JansenWJOssenkoppeleRKnolDL, et al.Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA2015; 313: 1924–1938.
11.
VogelAStokholmJAndreasenR, et al.Psychometric properties and reference data for Danish versions of free and cued selective reminding test, category cued memory test and logical memory. Scand J Psychol2018; 59: 496–502.
12.
VogelAJohannsenPStokholmJ, et al.Frequency and severity of semantic deficits in a consecutive memory clinic cohort. Dement Geriatr Cogn Disord2014; 38: 214–223.
13.
NielsenTRSegersKVanderaspoildenV, et al.Performance of middle-aged and elderly European minority and majority populations on a cross-cultural neuropsychological test battery (CNTB). Clin Neuropsychol2018; 32: 1411–1430.
14.
NielsenTRGrollenbergBURingkøbingSP, et al.The Copenhagen cross-linguistic naming test (C-CLNT): development and validation in a multicultural memory clinic population. J Int Neuropsychol Soc2023; 29: 911–921.
15.
PasquierFLeysDWeertsJGE, et al.Inter-and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol1996; 36: 268–272.
16.
FazekasFChawlukJAlaviA, et al.MR Signal abnormalities at 1.5T in Alzheimer’s dementia and normal aging. Am J Roentgenol1987; 149: 351–356.
17.
ScheltensPLaunerLJBarkhofF, et al.Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol1995; 242: 557–560.
18.
SimonsenAHMusaeusCSChristensenGL, et al.Upwards drift of cerebrospinal fluid amyloid-β 42 over twelve years in a consecutive clinical cohort. J Alzheimers Dis2021; 81: 1369–1373.
19.
DimopoulosKSimonsenAHGramkowMH, et al.Measurement of amyloid-β 1–42 in cerebrospinal fluid: a comparison of the second generation Elecsys and INNOTEST. Clin Chem Lab Med2023; 61: e182–e185.
20.
JessenFAmariglioREvan BoxtelM, et al.A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement2014; 10: 844–852.
21.
WinbladBPalmerKKivipeltoM, et al.Mild cognitive impairment – beyond controversies, towards a consensus: report of the international working group on mild cognitive impairment. J Intern Med2004; 256: 240–246.
22.
AlbertMSDeKoskySTDicksonD, et al.The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011; 7: 270–279.
23.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011; 7: 263–269.
24.
World Health Organization. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: World Health Organization, 1993.
25.
McKeithIGBoeveBFDicksonDW, et al.Diagnosis and management of dementia with Lewy bodies. Neurology2017; 89: 88–100.
26.
SachdevPKalariaRO’BrienJ, et al.Diagnostic criteria for vascular cognitive disorders. Alzheimer Dis Assoc Disord2014; 28: 206–218.
27.
RascovskyKHodgesJRKippsCM, et al.Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Dis Assoc Disord2007; 21: S14–S18.
28.
Gorno-TempiniMLHillisAEWeintraubS, et al.Classification of primary progressive aphasia and its variants. Neurology2011; 76: 1006–1014.
29.
HasselbalchSGCarlsenJFAlaouieMM, et al.Prediction of shunt response in idiopathic normal pressure hydrocephalus by combined lumbar infusion test and preoperative imaging scoring. Eur J Neurol2023; 30: 3047–3055.
30.
RelkinNMarmarouAKlingeP, et al.Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery2005; 57: S4–S16.
31.
HoffmannKSobolNAFrederiksenKS, et al.Moderate-to-high intensity physical exercise in patients with Alzheimer’s disease: a randomized controlled trial. J Alzheimers Dis2016; 50: 443–453.
32.
BruunMFrederiksenKSRhodius-MeesterHFM, et al.Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study. Alzheimers Res Ther2019; 11: 25.
33.
del CampoMMollenhauerBBertolottoA, et al.Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update. Biomark Med2012; 6: 419–430.
34.
TeunissenCETumaniHEngelborghsS, et al.Biobanking of CSF: international standardization to optimize biomarker development. Clin Biochem2014; 47: 288–292.
35.
SimonsenAHHerukkaS-KAndreasenN, et al.Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement2017; 13: 274–284.
36.
HerukkaSKSimonsenAHAndreasenN, et al.Recommendations for cerebrospinal fluid Alzheimer’s disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimers Dement2017; 13: 285–295.
37.
FrederiksenKSNielsenTRWinbladB, et al.European academy of neurology/European Alzheimer’s disease consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment. Eur J Neurol2021; 28: 2147–2155.
38.
FrederiksenKSNielsenTRAppollonioI, et al.Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: a European Alzheimer’s disease consortium survey. Int J Geriatr Psychiatry2021; 36: 324–333.
39.
GjerumLFrederiksenKSHenriksenOM, et al.Evaluating 2-[18F]FDG-PET in differential diagnosis of dementia using a data-driven decision model. Neuroimage Clin2020; 27: 102267.
40.
GjerumLFrederiksenKSHenriksenOM, et al.A visual rating scale for cingulate island sign on 18F-FDG-PET to differentiate dementia with Lewy bodies and Alzheimer’s disease. J Neurol Sci2020; 410: 116645.
41.
GramkowMHGjerumLKoikkalainenJ, et al.Prognostic value of complementary biomarkers of neurodegeneration in a mixed memory clinic cohort. PeerJ2020; 8: e9498.
42.
FrederiksenKSHasselbalchSGHejlAM, et al.Added diagnostic value of 11C-PiB-PET in memory clinic patients with uncertain diagnosis. Dement Geriatr Cogn Dis Extra2012; 2: 610–621.
43.
SimonsenAHMattilaJHejlAM, et al.Application of the PredictAD software tool to predict progression in patients with mild cognitive impairment. Dement Geriatr Cogn Disord2012; 34: 344–350.
44.
BruunMFrederiksenKSRhodius-MeesterHFM, et al.Impact of a clinical decision support tool on dementia diagnostics in memory clinics: the PredictND validation study. Curr Alzheimer Res2019; 16: 91–101.
45.
BruunMFrederiksenKSRhodius-MeesterHFM, et al.Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study. Alzheimers Res Ther2019; 11: 25.
46.
Thorlacius-UssingGBruunMGjerumL, et al.Comparing a single clinician versus a multidisciplinary consensus conference approach for dementia diagnostics. J Alzheimers Dis2021; 83: 741–751.
47.
GleerupHSSannaFHøghP, et al.Saliva neurofilament light chain is not a diagnostic biomarker for neurodegeneration in a mixed memory clinic population. Front Aging Neurosci2021; 13: 659898.
48.
MusaeusCSFrederiksenKSAndersenBB, et al.Detection of subclinical epileptiform discharges in Alzheimer’s disease using long-term outpatient EEG monitoring. Neurobiol Dis2023; 183: 106149.
49.
GramkowMHClemmensenFKSjællandNS, et al.Diagnostic performance of light reflex pupillometry in Alzheimer’s disease. Alzheimers Dement (Amst)2024; 16: e12628.
50.
CarlsenJFBacklundADLMardalCA, et al.Can shunt response in patients with idiopathic normal pressure hydrocephalus be predicted from preoperative brain imaging? A retrospective study of the diagnostic use of the normal pressure hydrocephalus radscale in 119 patients. AJNR Am J Neuroradiol2022; 43: 223–229.
51.
HasselbalchSGCarlsenJFAlaouieMM, et al.Prediction of shunt response in idiopathic normal pressure hydrocephalus by combined lumbar infusion test and preoperative imaging scoring. Eur J Neurol2023; 30: 3047–3055.
52.
SimonsenAHGleerupHSMusaeusCS, et al.Neurofilament light chain levels in serum among a large mixed memory clinic cohort: confounders and diagnostic usefulness. Alzheimers Dement (Amst)2023; 15: e12512.
53.
SimonsenAHBahlJMCDanborgPB, et al.Pre-analytical factors influencing the stability of cerebrospinal fluid proteins. J Neurosci Methods2013; 215: 234–240.
54.
SimonsenAHMusaeusCSChristensenGL, et al.Upwards drift of cerebrospinal fluid amyloid-β 42 over twelve years in a consecutive clinical cohort. J Alzheimers Dis2021; 81: 1369–1373.
55.
ZwanMDRinneJOHasselbalchSG, et al.Use of amyloid-PET to determine cutpoints for CSF markers. Neurology2016; 86: 50–58.
56.
LeitãoMJBaldeirasIHerukkaSK, et al.Chasing the effects of pre-analytical confounders – A multicenter study on CSF-AD biomarkers. Front Neurol2015; 6: 153.
57.
del CampoMMollenhauerBBertolottoA, et al.Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update. Biomark Med2012; 6: 419–430.
58.
LleóAAlcoleaDMartínez-LageP, et al.Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer’s disease continuum in the BIOMARKAPD study. Alzheimers Dement2019; 15: 742–753.
59.
DimopoulosKSimonsenAHGramkowMH, et al.Measurement of amyloid-β 1–42 in cerebrospinal fluid: a comparison of the second generation Elecsys and INNOTEST. Clin Chem Lab Med2023; 61: e182–e185.
60.
MusaeusCSGleerupHSHøghP, et al.Cerebrospinal fluid/plasma albumin ratio as a biomarker for blood-brain barrier impairment across neurodegenerative dementias. J Alzheimers Dis2020; 75: 429–436.
61.
JensenCSGleerupHSMusaeusCS, et al.Cerebrospinal fluid glucose is not altered in patients with dementia. Clin Biochem2023; 112: 1–5.
62.
VogelAStokholmJJørgensenK. Performances on rey auditory verbal learning test and rey complex figure test in a healthy, elderly Danish sample – reference data and validity issues. Scand J Psychol2012; 53: 26–31.
63.
VogelAStokholmJJørgensenK. Performances on symbol digit modalities test, color trails test, and modified stroop test in a healthy, elderly Danish sample. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn2013; 20: 370–382.
64.
JørgensenKKristensenMKWaldemarG, et al.The six-item clock drawing test – reliability and validity in mild Alzheimer’s disease. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn2015; 22: 301–311.
65.
VogelAJørgensenKLarsenIU. Normative data for emotion hexagon test and frequency of impairment in behavioral variant frontotemporal dementia, Alzheimer’s disease and Huntington’s disease. Appl Neuropsychol Adult2022; 29: 127–132.
66.
VogelAMellergaardCWaldemarG, et al.Impaired performances on the category cued memory test in mild Alzheimer’s disease and dementia with Lewy bodies: a comparative validity study. Appl Neuropsychol Adult2024; 31: 323–328.
67.
VogelABruusAEWaldemarG. Developing a Danish version of the LASSI-L test - reliability and predictive value in patients with mild cognitive impairment, mild dementia due to AD and subjective cognitive decline. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn2024; 31: 174–186.
68.
JørgensenKNielsenTRNielsenA, et al.Brief assessment of impaired cognition (BASIC)—validation of a new dementia case-finding instrument integrating cognitive assessment with patient and informant report. Int J Geriatr Psychiatry2019; 34: 1724–1733.
69.
JørgensenKNielsenTRNielsenA, et al.Validity of the brief assessment of impaired cognition case-finding instrument for identification of dementia subgroups and staging of dementia. Eur J Neurol2023; 30: 578–586.
70.
OxbøllA-BJørgensenKNielsenTR, et al.Diagnostic accuracy of BASIC-Q for detection of cognitive impairment in a primary care setting - a cross-validation study. BMC Geriatr2024; 24: 53.
71.
JørgensenKNielsenTRNielsenA, et al.Brief assessment of impaired cognition questionnaire (BASIC-Q)-development and validation of a new tool for identification of cognitive impairment in community settings. Int J Geriatr Psychiatry2020; 35: 693–701.
72.
NielsenTR. Cognitive assessment in culturally, linguistically, and educationally diverse older populations in Europe. Am J Alzheimers Dis Other Demen2022; 37: 153331752211170.
73.
NielsenTRNielsenDSWaldemarG. Barriers in access to dementia care in minority ethnic groups in Denmark: a qualitative study. Aging Ment Health2021; 25: 1424–1432.
74.
NielsenTRSegersKVanderaspoildenV, et al.Validation of the Rowland universal dementia assessment scale (RUDAS) in a multicultural sample across five western European countries: diagnostic accuracy and normative data. Int Psychogeriatr2019; 31: 287–296.
75.
NielsenTRSegersKVanderaspoildenV, et al.Validation of a brief multicultural cognitive examination (MCE) for evaluation of dementia. Int J Geriatr Psychiatry2019; 34: 982–989.
76.
NielsenTRSegersKVanderaspoildenV, et al.Validation of a European cross-cultural neuropsychological test battery (CNTB) for evaluation of dementia. Int J Geriatr Psychiatry2019; 34: 144–152.
77.
FranzenSWatermeyerTJPomatiS, et al.Cross-cultural neuropsychological assessment in Europe: position statement of the European consortium on cross-cultural neuropsychology (ECCroN). Clin Neuropsychol2022; 36: 546–557.
78.
NielsenTRAnteliusESpilkerRS, et al.Dementia care for people from ethnic minorities: a Nordic perspective. Int J Geriatr Psychiatry2015; 30: 217–218.
79.
Vinther-JensenTLarsenIUHjermindLE, et al.A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington’s disease. Orphanet J Rare Dis2014; 9: 114.
80.
Unmack LarsenIVinther-JensenTGadeA, et al.Assessing impairment of executive function and psychomotor speed in premanifest and manifest Huntington’s disease gene-expansion carriers. J Int Neuropsychol Soc2015; 21: 193–202.
81.
LarsenIUVinther-JensenTGadeA, et al.Do I misconstrue? Sarcasm detection, emotion recognition, and theory of mind in Huntington disease. Neuropsychology2016; 30: 181–189.
82.
HellemMNNHendelRKVinther-JensenT, et al.Endophenotypical drift in Huntington’s disease: a 5-year follow-up study. Orphanet J Rare Dis2021; 16: 340.
83.
HendelRKHellemMNNLarsenIU, et al.Impairments of social cognition significantly predict the progression of functional decline in Huntington’s disease: a 6-year follow-up study. Appl Neuropsychol Adult2022; 31: 777–786.
84.
HendelRKHellemMNNHjermindLE, et al.On the association between apathy and deficits of social cognition and executive functions in Huntington’s disease. J Int Neuropsychol Soc2023; 29: 369–376.
85.
von EssenMRHellemMNNVinther-JensenT, et al.Early intrathecal T helper 17.1 cell activity in Huntington disease. Ann Neurol2020; 87: 246–255.
86.
HellemMNNCheongRYTonettoS, et al.Decreased CSF oxytocin relates to measures of social cognitive impairment in Huntington’s disease patients. Parkinsonism Relat Disord2022; 99: 23–29.
87.
RoosPJohannsenPLindquistSG, et al.Six generations of CHMP2B -mediated frontotemporal dementia: clinical features, predictive testing, progression, and survival. Acta Neurol Scand2022; 145: 529–540.
88.
WardmanJHHenriksenEEMarthalerAG, et al.Enhancement of autophagy and solubilization of ataxin-2 alleviate apoptosis in spinocerebellar ataxia type 2 patient cells. Cerebellum2020; 19: 165–181.
89.
EjlerskovPHultbergJGWangJ, et al.Lack of neuronal IFN-β-IFNAR causes Lewy body- and Parkinson’s disease-like dementia. Cell2015; 163: 324–339.
90.
NehammerCEjlerskovPGopalS, et al.Interferon-β-induced miR-1 alleviates toxic protein accumulation by controlling autophagy. Elife2019; 8: e49930.
91.
PhungTKTAndersenBBHøghP, et al.Validity of dementia diagnoses in the Danish hospital registers. Dement Geriatr Cogn Disord2007; 24: 220–228.
92.
TaudorfLNørgaardAIslamoskaS, et al.Declining incidence of dementia: a national registry-based study over 20 years. Alzheimers Dement2019; 15: 1383–1391.
93.
TaudorfLNørgaardAWaldemarG, et al.Mortality in dementia from 1996 to 2015: a national registry-based cohort study. J Alzheimers Dis2021; 79: 289–300.
94.
DamsgaardLJanbekJLaursenTM, et al.Mapping morbidity 10 years prior to a diagnosis of young onset Alzheimer’s disease. Alzheimers Dement2024; 20: 2373–2383.
95.
Jensen-DahmCGasseCAstrupA, et al.Frequent use of opioids in patients with dementia and nursing home residents: a study of the entire elderly population of Denmark. Alzheimers Dement2015; 11: 691–699.
96.
NørgaardAJensen-DahmCGasseC, et al.Time trends in antipsychotic drug use in patients with dementia: a nationwide study. J Alzheimers Dis2015; 49: 211–220.
97.
NørgaardAJensen-DahmCGasseC, et al.Psychotropic polypharmacy in patients with dementia: prevalence and predictors. J Alzheimers Dis2017; 56: 707–716.
98.
KristensenRUNørgaardAJensen-DahmC, et al.Polypharmacy and potentially inappropriate medication in people with dementia: a nationwide study. J Alzheimers Dis2018; 63: 383–394.
99.
NørgaardAJensen-DahmCGasseC, et al.Association of benzodiazepines and antidepressants with 180-day mortality among patients with dementia receiving antipsychotic pharmacotherapy. J Clin Psychiatry2020; 81: 19m12828.
100.
PourhadiNJanbekJJensen-DahmC, et al.Proton pump inhibitors and dementia: a nationwide population-based study. Alzheimers Dement2024; 20: 837–845.
101.
SalemLCAndersenBBNielsenTR, et al.Inadequate diagnostic evaluation in young patients registered with a diagnosis of dementia: a nationwide register-based study. Dement Geriatr Cogn Dis Extra2014; 4: 31–44.
102.
ZakariasJKJensen-DahmCNørgaardA, et al.Geographical variation in antipsychotic drug use in elderly patients with dementia: a nationwide study. J Alzheimers Dis2016; 54: 1183–1192.
103.
Jensen-DahmCZakariasJKGasseC, et al.Geographical variation in opioid use in elderly patients with dementia: a nationwide study. J Alzheimers Dis2019; 70: 1209–1216.
104.
ZakariasJKJensen-DahmCNørgaardA, et al.Geographical variation in the diagnostic rate and quality of dementia diagnoses. J Alzheimers Dis2019; 69: 513–520.
105.
PhungTKTWaltoftBLLaursenTM, et al.Hysterectomy, oophorectomy and risk of dementia: a nationwide historical cohort study. Dement Geriatr Cogn Disord2010; 30: 43–50.
106.
DamsgaardLJanbekJLaursenTM, et al.Hospital-diagnosed sleep disorders and incident dementia: a nationwide observational cohort study. Eur J Neurol2022; 29: 3528–3536.
107.
JanbekJLaursenTMFrimodt-MøllerN, et al.Hospital-diagnosed infections, autoimmune diseases, and subsequent dementia incidence. JAMA Netw Open2023; 6: e2332635.
108.
PhungKTTChaayaMWaldemarG, et al.Validation of the 10/66 dementia research group diagnostic assessment for dementia in Arabic. J Geriatr Psychiatry Neurol2014; 27: 282–290.
109.
PhungTKTChaayaMAsmarK, et al.Performance of the 16-item informant questionnaire on cognitive decline for the elderly (IQCODE) in an Arabic-speaking older population. Dement Geriatr Cogn Disord2015; 40: 276–289.
110.
PhungKTTChaayaMPrinceM, et al.Dementia prevalence, care arrangement, and access to care in Lebanon: a pilot study. Alzheimers Dement2017; 13: 1317–1326.
111.
NielsenTRPhungTKTChaayaM, et al.Combining the Rowland universal dementia assessment scale and the informant questionnaire on cognitive decline in the elderly to improve detection of dementia in an Arabic-speaking population. Dement Geriatr Cogn Disord2016; 41: 46–54.
112.
ChaayaMPhungKAtwehS, et al.Dementia and family burden of care in Lebanon. BJPsych Int2017; 14: 7–9.
113.
ChaayaMPhungKAtwehS, et al.Socio-demographic and cardiovascular disease risk factors associated with dementia: results of a cross-sectional study from Lebanon. Prev Med Rep2018; 9: 1–5.
114.
DominguezJCPhungTKTde GuzmanMFP, et al.Determining Filipino normative data for a battery of neuropsychological tests: the Filipino norming project (FNP). Dement Geriatr Cogn Dis Extra2019; 9: 260–270.
115.
DominguezJde GuzmanMFChenSHA, et al.Filipino Multicomponent intervention to maintain cognitive performance in high-risk population (FINOMAIN): study protocol for a cluster randomized controlled trial. Front Neurol2021; 12: 685721.
116.
DominguezJJilocaLFowlerKC, et al.Dementia incidence, burden and cost of care: a Filipino community-based study. Front Public Health2021; 9: 628700.
117.
WaldemarGWaldorffFBBussDV, et al.The Danish Alzheimer intervention study: rationale, study design and baseline characteristics of the cohort. Neuroepidemiology2011; 36: 52–61.
118.
WaldorffFBBussDVEckermannA, et al.Efficacy of psychosocial intervention in patients with mild Alzheimer’s disease: the multicentre, rater blinded, randomised Danish Alzheimer intervention study (DAISY). Br Med J2012; 345: e4693–e4693.
119.
HoffmannKFrederiksenKSSobolNA, et al.Preserving cognition, quality of life, physical health and functional ability in Alzheimer’s disease: the effect of physical exercise (ADEX trial): rationale and design. Neuroepidemiology2013; 41: 198–207.
120.
HoffmannKSobolNAFrederiksenKS, et al.Moderate-to-high intensity physical exercise in patients with Alzheimer’s disease: a randomized controlled trial. J Alzheime’s Dis2016; 50: 443–453.
121.
SobolNAHoffmannKFrederiksenKS, et al.Effect of aerobic exercise on physical performance in patients with Alzheimer’s disease. Alzheimers Dement2016; 12: 1207–1215.
122.
SobolNADallCHHøghP, et al.Change in fitness and the relation to change in cognition and neuropsychiatric symptoms after aerobic exercise in patients with mild Alzheimer’s disease. J Alzheimers Dis2018; 65: 137–145.
123.
FrederiksenKSMadsenKAndersenBB, et al.Moderate- to high-intensity exercise does not modify cortical β-amyloid in Alzheimer’s disease. Alzheimers Dement (N Y)2019; 5: 208–215.
124.
Delgado-PerazaFNogueras-OrtizCSimonsenAH, et al.Neuron-derived extracellular vesicles in blood reveal effects of exercise in Alzheimer’s disease. Alzheimers Res Ther2023; 15: 156.
125.
JensenCSBahlJMØstergaardLB, et al.Exercise as a potential modulator of inflammation in patients with Alzheimer’s disease measured in cerebrospinal fluid and plasma. Exp Gerontol2019; 121: 91–98.
126.
ØksnebjergLWoodsBVilsenCR, et al.Self-management and cognitive rehabilitation in early stage dementia – merging methods to promote coping and adoption of assistive technology: a pilot study. Aging Ment Health2020; 24: 1894–1903.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
